Subtopic Deep Dive

PTX3 in Cancer Inflammation
Research Guide

What is PTX3 in Cancer Inflammation?

PTX3 serves as a humoral pattern recognition molecule with dual roles in modulating tumor-associated inflammation, suppressing angiogenesis, and exerting anti-metastatic effects in cancer microenvironments.

PTX3, a long pentraxin, acts in innate immunity and tissue repair while influencing cancer progression through regulation of inflammation (Garlanda et al., 2018, 196 citations). Studies show its expression in tumor stroma correlates with prognosis in cancers like clear cell renal cell carcinoma and glioblastoma (Netti et al., 2020, 167 citations; Tafani et al., 2011, 141 citations). Over 10 key papers from 2007-2020 explore its biomarker potential, with foundational work on vascular and antitumor roles (Presta et al., 2007, 175 citations; Germano et al., 2010, 263 citations).

Curated Papers

Key Challenges

Why It Matters

PTX3 expression in tumor microenvironments predicts outcomes in clear cell renal cell carcinoma, where high levels associate with better survival via immunoflogosis modulation (Netti et al., 2020). In myxoid liposarcoma, trabectedin targets PTX3-mediated inflammation to inhibit tumor growth (Germano et al., 2010). Proteomics identifies PTX3 as a lung cancer biomarker in conditioned media (Planque et al., 2009). These findings support PTX3 as a prognostic tool and therapeutic target, as detailed in reviews linking it to innate immunity and cancer remodeling (Garlanda et al., 2018; Doni et al., 2019).

Key Research Challenges

Context-Dependent Effects

PTX3 promotes anti-tumor immunity in some cancers but may enhance progression in others due to variable tumor microenvironment signals (Garlanda et al., 2018). This duality complicates biomarker validation across cancer types (Netti et al., 2020).

Prognostic Value Validation

Correlating PTX3 serum/tissue levels with survival requires larger cohorts beyond renal cell carcinoma studies (Netti et al., 2020, 167 citations). Conflicting expression patterns in glioblastoma hinder reliability (Tafani et al., 2011).

Therapeutic Targeting Mechanisms

Trabectedin modulates PTX3 in liposarcoma, but mechanisms in other cancers remain unclear (Germano et al., 2010). Angiogenesis suppression via PTX3 needs in vivo confirmation (Presta et al., 2007).

Essential Papers

Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells

Giovanni Germano, Roberta Frapolli, Matteo Simone et al. · 2010 · Cancer Research · 263 citations

Abstract Inflammatory mediators present in the tumor milieu may promote cancer progression and are considered promising targets of novel biological therapies. We previously reported that the marine...

PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer

Cecília Garlanda, Barbara Bottazzi, Elena Magrini et al. · 2018 · Physiological Reviews · 196 citations

Innate immunity includes a cellular and a humoral arm. PTX3 is a fluid-phase pattern recognition molecule conserved in evolution which acts as a key component of humoral innate immunity in infectio...

Association between human oocyte developmental competence and expression levels of some cumulus genes

F. Cillo, Tiziana A. L. Brevini, Stefania Antonini et al. · 2007 · Reproduction · 176 citations

Abstract At present, oocyte selection is mainly based upon morphological criteria but it is generally acknowledged that its reliability requires further improvement. The aim of this study was to de...

The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling

Barbara Bottazzi, Antonio Inforzato, Massimo Messa et al. · 2016 · Journal of Hepatology · 176 citations

Role of the soluble pattern recognition receptor PTX3 in vascular biology

Marco Presta, Maura Camozzi, Giovanni Salvatori et al. · 2007 · Journal of Cellular and Molecular Medicine · 175 citations

Introduction PTX3 gene and expression PTX3 protein structure PTX3 ligands PTX3 in vascular pathology Concluding remarks Abstract Pentraxins act as soluble pattern recognition receptors with a wide ...

PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma

Giuseppe Stefano Netti, Giuseppe Lucarelli, Federica Spadaccino et al. · 2020 · Aging · 167 citations

Pentraxin-3 (PTX3) belongs to the pentraxine family, innate immune regulators involved in angiogenesis, proliferation and immune escape in cancer. Here, we evaluated PTX3 tissue expression and seru...

Pentraxin 3 in Cardiovascular Disease

Giuseppe Ristagno, Francesca Fumagalli, Barbara Bottazzi et al. · 2019 · Frontiers in Immunology · 163 citations

The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The prototype of the pentrax...

Reading Guide

Foundational Papers

Start with Germano et al. (2010, 263 citations) for trabectedin-PTX3 antitumor effects and Presta et al. (2007, 175 citations) for vascular biology roles, as they establish core mechanisms before cancer-specific studies.

Recent Advances

Study Netti et al. (2020, 167 citations) for renal carcinoma prognosis and Doni et al. (2019, 152 citations) for innate immunity-cancer links to capture advances in biomarker validation.

Core Methods

Core techniques: Proteomics (Planque et al., 2009), gene expression in microenvironments (Tafani et al., 2011), serum/tissue correlation (Netti et al., 2020), and functional assays with inflammatory modulators (Germano et al., 2010).

How PapersFlow Helps You Research PTX3 in Cancer Inflammation

Discover & Search

Research Agent uses searchPapers('PTX3 cancer inflammation') to retrieve top papers like Netti et al. (2020), then citationGraph to map 167+ citations linking to Garlanda et al. (2018). findSimilarPapers on Germano et al. (2010) uncovers trabectedin-related works; exaSearch drills into tumor microenvironment expression data.

Analyze & Verify

Analysis Agent applies readPaperContent on Netti et al. (2020) to extract PTX3 prognostic stats, verifyResponse with CoVe to cross-check survival correlations against Garlanda et al. (2018), and runPythonAnalysis for meta-analysis of expression levels across 10 papers using pandas for cohort comparisons. GRADE grading scores evidence strength for renal carcinoma biomarker claims.

Synthesize & Write

Synthesis Agent detects gaps in PTX3's dual roles via contradiction flagging between Netti (anti-tumor) and Tafani (pro-inflammatory); Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate 263 Germano citations, latexCompile for figures, and exportMermaid for inflammation pathway diagrams.

Use Cases

"Run statistical analysis on PTX3 expression vs survival data from renal cancer papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas survival curves from Netti 2020 + 5 similar papers) → matplotlib plot of hazard ratios.

"Draft LaTeX review section on PTX3 in tumor inflammation with citations"

Synthesis Agent → gap detection → Writing Agent → latexEditText (intro para) → latexSyncCitations (Garlanda 2018, Netti 2020) → latexCompile → PDF with diagram.

"Find code for PTX3 proteomics analysis in lung cancer papers"

Research Agent → paperExtractUrls (Planque 2009) → paperFindGithubRepo → Code Discovery → githubRepoInspect → exportCsv of biomarker pipelines.

Automated Workflows

Deep Research workflow scans 50+ PTX3 papers via searchPapers → citationGraph → structured report on inflammation roles with GRADE scores. DeepScan's 7-step chain verifies Netti (2020) claims against Germano (2010) using CoVe checkpoints and runPythonAnalysis for stats. Theorizer generates hypotheses on PTX3-trabectedin synergies from 10 core papers.

Try Doxa for PTX3 in Cancer Inflammation Research

Frequently Asked Questions

What is PTX3's definition in cancer inflammation?

PTX3 is a long pentraxin and humoral pattern recognition molecule that modulates tumor-associated inflammation, angiogenesis, and metastasis (Garlanda et al., 2018).

What are key methods studying PTX3 in cancer?

Methods include immunohistochemistry for tumor stroma expression (Netti et al., 2020), proteomics of conditioned media (Planque et al., 2009), and trabectedin assays for anti-inflammatory effects (Germano et al., 2010).

What are key papers on PTX3 in cancer?

Top papers: Germano et al. (2010, 263 citations) on liposarcoma; Netti et al. (2020, 167 citations) on renal carcinoma prognosis; Garlanda et al. (2018, 196 citations) review.

What open problems exist for PTX3 as cancer biomarker?

Challenges include resolving context-dependent pro/anti-tumor effects and validating prognostic value beyond renal cell carcinoma in larger multi-cancer cohorts (Doni et al., 2019; Tafani et al., 2011).